An integrative approach to identifying cancer chemoresistance-associated pathways

BMC Medical Genomics

Volumn 4, Issue , 2011, Pages

  Chao, Shih Yi ^a   Chiang, Jung Hsien ^b   Huang, A Mei ^c   Chang, Woan Shan ^b  

^a CHING YUN UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN DELTA; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PROTEIN KINASE B BETA; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER RESISTANCE; CHEMOSENSITIVITY; GENE IDENTIFICATION; GENE INTERACTION; GENE REGULATORY NETWORK; GENETIC DATABASE; LUNG CANCER; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ALGORITHM; DRUG RESISTANCE; FACTUAL DATABASE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MICROARRAY ANALYSIS; OVARY TUMOR;

ALGORITHMS; ANTINEOPLASTIC AGENTS; DATABASES, FACTUAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; MICROARRAY ANALYSIS; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 79953103271     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-4-23     Document Type: Article

References (50)

1. Bosch TM: Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol 2008, 448:63-76.
2. Meisel P: Arylamine N-acetyltransferases and drug response. Pharmacogenomics 2002, 3(3):349-366.
3. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2(1):48-58. (Pubitemid 37328807)
4. Hembruff SL, Laberge ML, Villeneuve DJ, Guo B, Veitch Z, Cecchetto M, Parissenti AM: Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance. BMC Cancer 2008, 8:318.
5. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, et al: Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005, 5(1):15-27. (Pubitemid 40081291)
6. Liu LZ, Zhou XD, Qian G, Shi X, Fang J, Jiang BH: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007, 67(13):6325-6332. (Pubitemid 47037515)
7. Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005, 4(1):25.
8. Kang HC, Kim IJ, Park JH, Shin Y, Ku JL, Jung MS, Yoo BC, Kim HK, Park JG: Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. Clin Cancer Res 2004, 10(1 Pt 1):272-284. (Pubitemid 38114190)
9. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K, Toge T, Yahata H, Tanaka S, Chayama K, et al: Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 2004, 111(4):617-626. (Pubitemid 39045331)
10. Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T: Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther 2005, 4(3):399-412. (Pubitemid 40443925)
11. Cabusora L, Sutton E, Fulmer A, Forst CV: Differential network expression during drug and stress response. Bioinformatics 2005, 21(12):2898-2905. (Pubitemid 40862290)
12. Riedel RF, Porrello A, Pontzer E, Chenette EJ, Hsu DS, Balakumaran B, Potti A, Nevins J, Febbo PG: A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008, 7(10):3141-3149.
13. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33(1):9-23. (Pubitemid 46137553)
14. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7(8):573-584.
15. Schaefer CF, Anthony K, Krupa S, Buchoff J, Day M, Hannay T, Buetow KH: PID: the Pathway Interaction Database. Nucleic Acids Res 2009,, 37 Database: D674-679.
16. Matys V, Fricke E, Geffers R, Gossling E, Haubrock M, Hehl R, Hornischer K, Karas D, Kel AE, Kel-Margoulis OV, et al: TRANSFAC: transcriptional regulation, from patterns to profiles. Nucleic Acids Res 2003, 31(1):374-378. (Pubitemid 36150406)
17. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, Katayama T, Kawashima S, Okuda S, Tokimatsu T, et al: KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008, , 36 Database: D480-484.
18. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M: From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 2006,, 34 Database: D354-357.
19. Peters D, Freund J, Ochs RL: Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 2005, 4(10):1605-1616. (Pubitemid 41556444)
20. Almeida GM, Duarte TL, Farmer PB, Steward WP, Jones GD: Multiple endpoint analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing. Int J Cancer 2008, 122(8):1810-1819. (Pubitemid 351413428)
21. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, Kim IF, Soboleva A, Tomashevsky M, Marshall KA, et al: NCBI GEO: archive for high-throughput functional genomic data. Nucleic Acids Res 2009,, 37 Database: D885-890.
22. Yen JY: Finding the K Shortest Loopless Paths in a Network. Management Science 1971, 17(11):712-716.
23. Hour TC, Lai YL, Kuan CI, Chou CK, Wang JM, Tu HY, Hu HT, Lin CS, Wu WJ, Pu YS, et al: Transcriptional up-regulation of SOD1 by CEBPD: a potential target for cisplatin resistant human urothelial carcinoma cells. Biochem Pharmacol 2010, 80(3):325-334.
24. Wood RD, Mitchell M, Lindahl T: Human DNA repair genes, 2005. Mutat Res 2005, 577(1-2):275-283.
25. Kohno K, Uchiumi T, Niina I, Wakasugi T, Igarashi T, Momii Y, Yoshida T, Matsuo K, Miyamoto N, Izumi H: Transcription factors and drug resistance. Eur J Cancer 2005, 41(16):2577-2586. (Pubitemid 41540632)
26. Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP: C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene 2005, 24(9):1589-1597. (Pubitemid 40396088)
27. Huang AM, Montagna C, Sharan S, Ni Y, Ried T, Sterneck E: Loss of CCAAT/enhancer binding protein delta promotes chromosomal instability. Oncogene 2004, 23(8):1549-1557. (Pubitemid 38406517)
28. Sanford DC, DeWille JW: C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate 2005, 63(2):143-154. (Pubitemid 40525364)
29. Thangaraju M, Rudelius M, Bierie B, Raffeld M, Sharan S, Hennighausen L, Huang AM, Sterneck E: C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development 2005, 132(21):4675-4685. (Pubitemid 41685278)
30. Ideker T, Ozier O, Schwikowski B, Siegel AF: Discovering regulatory and signalling circuits in molecular interaction networks. Bioinformatics 2002, 18(Suppl 1):S233-240.
31. Matthews L, Gopinath G, Gillespie M, Caudy M, Croft D, de Bono B, Garapati P, Hemish J, Hermjakob H, Jassal B, et al: Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res 2009,, 37 Database: D619-622.
32. Eltabbakh GH, Awtrey CS: Current treatment for ovarian cancer. Expert Opin Pharmacother 2001, 2(1):109-124. (Pubitemid 32427718)
33. Hibi K, Takahashi T, Sekido Y, Ueda R, Hida T, Ariyoshi Y, Takagi H: Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991, 6(12):2291-2296. (Pubitemid 21924076)
34. Krystal GW, Hines SJ, Organ CP: Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996, 56(2):370-376.
35. Raspollini MR, Amunni G, Villanucci A, Baroni G, Taddei A, Taddei GL: c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann Oncol 2004, 15(4):594-597. (Pubitemid 38559594)
36. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4(12):988-1004.
37. Ohta T, Ohmichi M, Hayasaka T, Mabuchi S, Saitoh M, Kawagoe J, Takahashi K, Igarashi H, Du B, Doshida M, et al: Inhibition of phosphatidylinositol 3-kinase increases efficacy of cisplatin in in vivo ovarian cancer models. Endocrinology 2006, 147(4):1761-1769.
38. Lee S, Choi EJ, Jin C, Kim DH: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005, 97(1):26-34. (Pubitemid 40403670)
39. L'Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Tetu B, Bachvarov D: Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 2006, 29(1):5-24.
40. Hintze A, Adami C: Evolution of complex modular biological networks. PLoS Comput Biol 2008, 4(2):e23.
41. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22(47):7265-7279.
42. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E: AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004, 94(3):785-795. (Pubitemid 39194476)
43. Ali IU, Schriml LM, Dean M: Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999, 91(22):1922-1932.
44. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK: The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998, 95(23):13513-13518. (Pubitemid 28523003)
45. Gatcliffe TA, Monk BJ, Planutis K, Holcombe RF: Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer 2008, 18(5):954-962.
46. Ricken A, Lochhead P, Kontogiannea M, Farookhi R: Wnt signaling in the ovary: identification and compartmentalized expression of wnt-2, wnt- 2b, and frizzled-4 mRNAs. Endocrinology 2002, 143(7):2741-2749. (Pubitemid 34701338)
47. Yao HH, Matzuk MM, Jorgez CJ, Menke DB, Page DC, Swain A, Capel B: Follistatin operates downstream of Wnt4 in mammalian ovary organogenesis. Dev Dyn 2004, 230(2):210-215. (Pubitemid 38669583)
48. Wang Z, Li Y, Banerjee S, Sarkar FH: Emerging role of Notch in stem cells and cancer. Cancer Lett 2009, 279(1):8-12.
49. Dobrzycka B, Terlikowski SJ, Kowalczuk O, Niklinska W, Chyczewski L, Kulikowski M: Mutations in the KRAS gene in ovarian tumors. Folia Histochem Cytobiol 2009, 47(2):221-224.
50. Auner V, Kriegshauser G, Tong D, Horvat R, Reinthaller A, Mustea A, Zeillinger R: KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009, 9:111.